Skye Bioscience, Inc.
SKYE· Nasdaq
SKYESkye Bioscience, Inc.
Released Mar 10, 2026, after the close
10-K filed Mar 10, 2026, 69 days after period end · 0001628280-26-016394
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$14.44M | -$9.75M | -$4.42M | -$9.89M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Skye Bioscience, Inc. · CIK 1516551 · Engraved from SEC EDGAR
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
ended Dec 31, 2025 · filed Mar 10, 2026 · 69 d after period end
10.0% from the close of Mar 10, 2026 to the close of Mar 11, 2026, the first after the release.
